Tau Imaging in Professional Fighters

• Status: Completed
• Trial end date: 2017-02-03
• Target enrollment: 0
• Participant gender: Male

Summary

Subjects enrolled in the Professional Fighters Brain Health Study (PFBHS) will receive flortaucipir to explore its use as a biomarker for brain injury related to repetitive head trauma and to examine the relationship between clinical presentation and tau deposition.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Avid Radiopharmaceuticals
• Collaborator: The Cleveland Clinic

Criteria

Inclusion Criteria:

All Subjects

• Currently enrolled in the PFBHS protocol and have participated in a minimum of 10 professional fights

• Can tolerate Positron Emission Tomography (PET) scan procedures

• Have the ability to provide informed consent

Subjects with cognitive impairment

• Have subjective cognitive complaints or objective decline or impairment as determined by the investigator

Exclusion Criteria:

• Have behavior dysfunction that is likely to interfere with imaging

• Are claustrophobic or otherwise unable to tolerate the imaging procedure

• Have current clinically significant cardiovascular disease or clinically significant abnormalities on screening electrocardiogram

• A history of additional risk factors for Torsades de Pointes (TdP) or are taking drugs that are known to cause QT-prolongation

• Have a current clinically significant infectious disease, endocrine or metabolic disease, pulmonary, renal or hepatic impairment, or cancer

• Have had a non-study related radiopharmaceutical imaging or treatment procedure within 7 days prior to the study imaging session

• Have current drug or alcohol dependence or alcohol dependence within the past 2 years